Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Dosage

6 evidence topics · 5 sources

Crizotinib label: dose reduction levels for adults, with 200 mg twice daily as the first reduction
Dose reduction level for adult patients with NSCLC or IMTDose and schedule
First dose reduction“200 mg twice daily”
Second dose reduction“250 mg once daily”